A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression

Journal of Clinical Psychiatry

Volumn 58, Issue 11, 1997, Pages 484-491

  Lydiard, R Bruce ^a   Stahl, Stephen M ^d   Hertzman, Marc ^b   Harrison, Wilma M ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CHLORAL HYDRATE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; NORTRIPTYLINE; PLACEBO; SERTRALINE; TEMAZEPAM;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; NEUROTRANSMITTER RELEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SOMNOLENCE; TREMOR; VERTIGO; XEROSTOMIA;

EID: 0030666692     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n1104     Document Type: Article

References (28)

1. Kiloh L, Andrews G, Neilson M. Long-term outcome of depressive illness. Br J Psychiatry 1988;153:752-757
2. Fawcett J. Morbidity of clinical depression. Int Clin Psychopharmacol 1993;8:217-220
3. Lee A, Murray R. Long-term outcome of Maudsley depressives. Br J Psychiatry 1988;153:741-751
4. Agosti V, Stewart J, Quitkin F. Life satisfaction and psychosocial functioning in chronic depression: effect of acute treatment with antidepressant. J Affect Disord 1991;23:35-41
5. Frank E, Kupfer D, Bulik C, et al. Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord 1990;20:165-172
6. Henry JA. A fatal toxicity index for antidepressant poisoning. Acta Psychiatr Scand Suppl 1989;80(suppl 354):37-45
7. Montgomery SA, Baldwin D, Green M. Why do amitriptyline and dothiepin appear to be so dangerous in overdose? Acta Psychiatr Scand Suppl 1989;80(suppl 354):47-53
8. Corruble E, Puech A. How to improve the risk-benefit ratio of antidepressants. Int Clin Psychopharmacol 1993;8:237-241
9. Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 1992;149:795-800
10. Doogan D, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-222
11. Kasper S. Rationale for long-term antidepressant therapy. Int Clin Psychopharmacol 1993;8:225-235
12. Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990;51(12, suppl B):28-33
13. Mesters P, Cosyns P, Dejaiffe G, et al. Assessment of quality of life in the treatment of major depressive disorder with fluoxetine, 20 mg, in ambulatory patients aged over 60 years. Int Clin Psychopharmacol 1993;8: 337-340
14. Sullivan G, Wells K, Leake B. Clinical factors associated with better quality of life in a seriously mentally ill population. Hospital and Community Psychiatry 1992;8:794-798
15. Jaeschke R, Guyatt GH, Cook D. Quality of life instruments in the evaluation of new drugs. PharmacoEconomics 1992;1(2):84-94
16. Fletcher A, Gore S, Jones D, et al. Quality of life measures in health care, II: design, analysis, and interpretation. BMJ 1992;305:1145-1148
17. IMS America Audited Prescription Data 1990 and 1997. Plymouth Meeting, Pa
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
20. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771
21. Montgomery SA, Asberg M. A new depression rating scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
22. Endicott J, Nee J, Harrison W, et al. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993;29: 321-326
23. Revicki D, Turner R, Brown R, et al. Reliability and validity of a Health-Related Quality of Life battery for evaluating outpatient antidepressant treatment. Qual Life Res 1992;1:257-266
24. McNair DM, Lorr M, Droppleman LF, et al. Profile of Mood States. San Diego, Calif: Educational and Industrial Testing Service; 1971
25. Beck AT, Ward CH, Mendelson M, et al. Inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
26. Sclar D, Robison L, Skaer T, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 4:715-729
27. Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995;38:592-602
28. Agency for Health Care Policy and Research. Clinical Practice Guideline: Depression in Primary Care, vol 2. (AHCPR publication 93-0551). Washington, DC: US Government Printing Office; 1994:56